Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Raeberali, Lucknow 226002, India.
Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER)-Raeberali, Lucknow 226002, India.
ACS Chem Neurosci. 2021 Aug 4;12(15):2776-2797. doi: 10.1021/acschemneuro.1c00353. Epub 2021 Jul 14.
Common symptoms such as dizziness, headache, olfactory dysfunction, nausea, vomiting, etc. in COVID-19 patients have indicated the involvement of the nervous system. However, the exact association of the nervous system with COVID-19 infection is still unclear. Thus, we have conducted a meta-analysis of clinical studies associated with neurological problems in COVID-19 patients. We have searched for electronic databases with MeSH terms, and the studies for analysis were selected based on inclusion and exclusion criteria and quality assessment. The Stats Direct (version 3) was used for the analysis. The pooled prevalence with 95% confidence interval of various neurological manifestations reported in the COVID-19 patients was found to be headache 14.6% (12.2-17.2), fatigue 33.6% (29.5-37.8), olfactory dysfunction 26.4% (21.8-31.3), gustatory dysfunction 27.2% (22.3-32.3), vomiting 6.7% (5.5-8.0), nausea 9.8% (8.1-11.7), dizziness 6.7% (4.7-9.1), myalgia 21.4% (18.8-24.1), seizure 4.05% (2.5-5.8), cerebrovascular diseases 9.9% (6.8-13.4), sleep disorders 14.9% (1.9-36.8), altered mental status 17.1% (12.3-22.5), neuralgia 2.4% (0.8-4.7), arthralgia 19.9% (15.3-25.0), encephalopathy 23.5% (14.3-34.1), encephalitis 0.6% (0.2-1.3), malaise 38.3% (24.7-52.9), confusion 14.2% (6.9-23.5), movement disorders 5.2% (1.7-10.4), and Guillain-Barre syndrome 6.9% (2.3-13.7). However, the heterogeneity among studies was found to be high. Various neurological manifestations related to the central nervous system (CNS) and peripheral nervous system (PNS) are associated with COVID-19 patients.
新型冠状病毒肺炎（COVID-19）患者常出现头晕、头痛、嗅觉功能障碍、恶心、呕吐等症状，表明其神经系统受累。然而，COVID-19 感染与神经系统的确切关联尚不清楚。因此，我们对 COVID-19 患者神经系统问题相关的临床研究进行了荟萃分析。我们检索了电子数据库，使用 MeSH 术语，并根据纳入和排除标准以及质量评估选择了分析研究。使用 Stats Direct（版本 3）进行分析。发现 COVID-19 患者报告的各种神经系统表现的合并患病率及其 95%置信区间为：头痛 14.6%（12.2-17.2），乏力 33.6%（29.5-37.8），嗅觉功能障碍 26.4%（21.8-31.3），味觉功能障碍 27.2%（22.3-32.3），呕吐 6.7%（5.5-8.0），恶心 9.8%（8.1-11.7），头晕 6.7%（4.7-9.1），肌痛 21.4%（18.8-24.1），癫痫发作 4.05%（2.5-5.8），脑血管疾病 9.9%（6.8-13.4），睡眠障碍 14.9%（1.9-36.8），精神状态改变 17.1%（12.3-22.5），神经痛 2.4%（0.8-4.7），关节痛 19.9%（15.3-25.0），脑病 23.5%（14.3-34.1），脑炎 0.6%（0.2-1.3），不适 38.3%（24.7-52.9），意识模糊 14.2%（6.9-23.5），运动障碍 5.2%（1.7-10.4），以及吉兰-巴雷综合征 6.9%（2.3-13.7）。然而，研究间的异质性较高。与 COVID-19 患者相关的各种中枢神经系统（CNS）和周围神经系统（PNS）相关的神经系统表现。
